ME Therapeutics Holding (XCNQ:METX) Interest Expense : C$0.00 Mil (TTM As of Feb. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ME Therapeutics Holding's interest expense for the three months ended in Feb. 2024 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ME Therapeutics Holding's Operating Income for the three months ended in Feb. 2024 was C$ -0.15 Mil. ME Therapeutics Holding's Interest Expense for the three months ended in Feb. 2024 was C$ 0.00 Mil. ME Therapeutics Holding has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

ME Therapeutics Holding Interest Expense Historical Data

The historical data trend for ME Therapeutics Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Interest Expense Chart

ME Therapeutics Holding Annual Data

Trend

Aug22

Aug23

Interest Expense

-0.01

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

ME Therapeutics Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

ME Therapeutics Holding (XCNQ:METX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ME Therapeutics Holding's Interest Expense for the three months ended in Feb. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Feb. 2024 was C$-0.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2024 was C$0.00 Mil.

ME Therapeutics Holding's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as

ME Therapeutics Holding had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. ME Therapeutics Holding Inc has enough cash to cover all of its debt. Its financial situation is stable.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

Q9T:Germany

Address

177 Robson Street, Vancouver, BC, CAN, V6B 0N3

Website

https://www.metherapeutics.com

ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines